Savaria Corp (SIS.TO) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Savaria Corp (SIS.TO)

Wealthica The ultimate 360° Tracker Your financial life in one place, automatically

29.11

+0.49 (1.71%)

as of Jun 5, 2026, 8:00:00 pm Market Open.

307 watching

Investor Insights

Jun 5, 2026, 12:00 am

This summary was created by AI, based on 6 opinions in the last 12 months.

Savaria Corp (SIS-T) is experiencing a positive momentum due to its focus on the accessibility industry amidst a demographic trend of an aging population that prefers to age at home. Following challenges from tariffs that impacted its operations, the company has strategically shifted its production to the U.S. and is now compliant with CUSMA regulations, which helps in stabilizing its market position. Analysts note that a significant portion of its products is FDA-regulated, shielding them from tariff impacts. The company has shown resilience and growth potential, combined with cost-cutting measures and the introduction of new products. Its current yield of 2.69% and analysts' target price suggest prospects of further appreciation in stock value, making it an attractive long-term investment.

Consensus

Positive

Valuation

Fair Value

Similar

Amedisys, AMED

WATCH

Management has lots of skin in the game. Challenges over Covid gaining access to LTC homes. Input costs have increased. Wants to see margins stabilize before getting back in. Don't rush to buy until you see that for a couple more quarters. Likes the fundamentals. Aging population provides a tailwind.

TOP PICK

Transformative acquisition last year made them largest player in sector. Record backlog of orders. Management suggesting record financial results for the coming year. Stock price down 30% is presenting excellent price to buy. Aging population providing tailwinds on business model.

HOLD

Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. The stock is down 12% YTD but 5i remains comfortable with it. It is not the only stock to have a tough year so far. Not a lot of choice in the sector. Potential is still good. Unlock Premium - Try 5i Free

PAST TOP PICK

(A Top Pick Aug 10/20, Up 5.35%) Expects demand for long term care facilities to increase. Has sold shares in company. If management team meets guidance, will be a good stock to buy. Wait to buy more shares.

PARTIAL BUY

He owned this until last year, selling it because the PE got high. This stock depends on aging demographics. For this reason, he's keeping it on his radar. Not a bad choice for your portfolio.

PAST TOP PICK

(A Top Pick Apr 28/21, Down 2.9%) They made a transformative acquisition of Sweden's Handicare to make Savaria the largest player in this space--major synergies. A few days ago they reported a very good quarter: surpassed $100 million EBITDA target, a record backlog, and are guiding $120-130 million EBITDA in 2022, an increase of 14%. The stock has fallen 20% from its highs, but now is a very good entry point--he is buying at these levels. Aging demographics are a strong tailwind as seniors prefer to stay at home longer and not move into long-term care. Well-managed and trades at a reasonable valuation.

HOLD

Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. Could continue to hold for income and growth. The valuation is more moderate at 21x earnings. The higher debt they took on over the last year is probably the cause. Less attractive than before. Growth is expected to be good and it could recover in a better market. Unlock Premium - Try 5i Free

BUY

Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. The company continues to integrate their large acquisition from last year. Their debt has increased but sales and EPS is expected to rise. The business should be somewhat resilient if the economy weakens. The dividend has increased also. Unlock Premium - Try 5i Free

HOLD

Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. EPS missed by 1 cent while revenues matched estimates. Revenue doubled but EPS fell yoy. Freight costs were a big drag on margins. Good growth is still expected next year. Could flatline for a bit, depending on how inflation plays out. Unlock Premium - Try 5i Free

BUY

Tailwinds over the next few years. Accretive acquisitions will add to market cap and bottom line. By pulling synergies out, margins can improve. Not the largest margin business, so they have to be careful. Market has been impressed, hitting all-time highs.

PAST TOP PICK

(A Top Pick Jun 05/20, Up 48%) A good year for Savaria. Likes it a lot. The pandemic has helped their prospects. The demographics of aging is supportive of the company. Used the stock market panic to step in. There is now a rebound in general market confidence as well with demographic trends. Increasing scale and geographical footprint. More to come from this company.

BUY

Allan Tong’s Discover Picks After years of ups and downs, Savaria turned a corner last winter when it bought Handicare to double the company’s size and become the global market leader. Of course, the underlying tailwind remains aging demographics. It’s a lot cheaper for a senior to install an elevator in their home than to move into a residence. Also, how Covid ravaged nursing homes in 2020 is tragically fresh on everyone’s minds. Savaria’s last four quarters actually saw two beats and two misses in earnings, so the street is betting on the future. For example, SIS stock’s EPS estimate for Q4 2021 is 22 cents compared to the actual 13 cents of Q4 2020. There’s still upside here, so this is definitely a buy. Read 3 Hot TSX Stocks for our full analysis.

TOP PICK

World leader in home accessibility. Transformative acquisition doubled the company's size. Expecting large synergies in revenue and costs. Great way to play aging demographics, plus trend to stay at home. Unique space. Yield is 2.57%. (Analysts’ price target is $21.69)

BUY

A growth by acquisition. They install lifts for seniors in their homes, and this aging demographic is a major tailwind. They put up some good quarters and is reasonably valued. SIS is high on his watch list. Respects management team. This stock should do well coming out of the pandemic for the coming year.

BUY

Quite interesting. Like other healthcare stocks, SIS has a tailwind in demographics that'll continue to build their business. Often in Canada, investors focus on a few businesses, so this stock had a big move up, then went through a sideways consolidation period. Recently, they made a big purchase which didn't surprise him--he's now looking at it. The current valuation is quite compelling. When this Swedish deal is completed, it could drive the stock up.

Showing 31 to 45 of 126 entries

Most Recent Experts

Brian Madden

First Avenue Investment Counsel

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Darren Sissons

Campbell Lee & Ross

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

Joe Terranova

Virtus Investment Partners

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Savaria Corp (SIS.TO)